ProShare Advisors
RIGL icon

ProShare Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

ProShare Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,075
Closed -$45.5K – 1973
2024
Q1 		$45.5K Buy
3,075
+242
+9% +$3.26K ﹤0.01% 1918
2023
Q4 		$41.1K Buy
2,833
+610
+27% +$6.24K ﹤0.01% 1880
2023
Q3 		$24K Sell
2,223
-3
-0.1% -$36 ﹤0.01% 1772
2023
Q2 		$28.7K Buy
2,226
+195
+10% +$2.64K ﹤0.01% 1817
2023
Q1 		$26.8K Sell
2,031
-190
-9% -$3.02K ﹤0.01% 1718
2022
Q4 		$33.3K Sell
2,221
-1,135
-34% -$10.4K ﹤0.01% 1775
2022
Q3 		$40K Buy
3,356
+77
+2% +$1.04K ﹤0.01% 1680
2022
Q2 		$37K Sell
3,279
-1,694
-34% -$34K ﹤0.01% 1737
2022
Q1 		$149K Sell
4,973
-1,168
-19% -$31.6K ﹤0.01% 1955
2021
Q4 		$163K Buy
6,141
+302
+5% +$9.11K ﹤0.01% 2099
2021
Q3 		$212K Sell
5,839
-1,651
-22% -$65K ﹤0.01% 1765
2021
Q2 		$325K Buy
7,490
+617
+9% +$23.3K ﹤0.01% 1845
2021
Q1 		$235K Buy
6,873
+500
+8% +$19.8K ﹤0.01% 1941
2020
Q4 		$223K Buy
6,373
+1,567
+33% +$45.4K ﹤0.01% 1796
2020
Q3 		$115K Sell
4,806
-197
-4% -$4.84K ﹤0.01% 1512
2020
Q2 		$92K Buy
5,003
+1,712
+52% +$30.8K ﹤0.01% 1576
2020
Q1 		$51K Sell
3,291
-2,614
-44% -$55.6K ﹤0.01% 1117
2019
Q4 		$126K Sell
5,905
-548
-8% -$11.3K ﹤0.01% 1667
2019
Q3 		$121K Sell
6,453
-205
-3% -$4.24K ﹤0.01% 1529
2019
Q2 		$174K Sell
6,658
-846
-11% -$19.1K ﹤0.01% 1467
2019
Q1 		$193K Buy
7,504
+87
+1% +$1.99K ﹤0.01% 1484
2018
Q4 		$171K Sell
7,417
-1,424
-16% -$40.2K ﹤0.01% 1404
2018
Q3 		$284K Sell
8,841
-207
-2% -$6.21K ﹤0.01% 1391
2018
Q2 		$256K Buy
9,048
+384
+4% +$13.7K ﹤0.01% 1473
2018
Q1 		$307K Sell
8,664
-1,424
-14% -$57K ﹤0.01% 1307
2017
Q4 		$391K Buy
10,088
+2,218
+28% +$84.4K ﹤0.01% 1254
2017
Q3 		$200K Buy
7,870
+493
+7% +$12K ﹤0.01% 1286
2017
Q2 		$201K Sell
7,377
-568
-7% -$15.5K ﹤0.01% 1347
2017
Q1 		$263K Sell
7,945
-197
-2% -$5.02K ﹤0.01% 1301
2016
Q4 		$194K Buy
8,142
+1,269
+18% +$36.3K ﹤0.01% 1605
2016
Q3 		$252K Sell
6,873
-1,125
-14% -$32.3K ﹤0.01% 1221
2016
Q2 		$178K Buy
7,998
+414
+5% +$10.3K ﹤0.01% 1451
2016
Q1 		$158K Sell
7,584
-818
-10% -$20.2K ﹤0.01% 1458
2015
Q4 		$255K Buy
+8,402
New +$255K ﹤0.01% 1393
2015
Q3 		– Sell
-1,112
Closed -$36K – 1525
2015
Q2 		$36K Sell
1,112
-579
-34% -$22.1K ﹤0.01% 1624
2015
Q1 		$60K Sell
1,691
-151
-8% -$4.14K ﹤0.01% 1852
2014
Q4 		$42K Sell
1,842
-6,119
-77% -$124K ﹤0.01% 1928
2014
Q3 		$154K Sell
7,961
-1,567
-16% -$44.3K ﹤0.01% 2061
2014
Q2 		$346K Sell
9,528
-5,979
-39% -$203K ﹤0.01% 1812
2014
Q1 		$602K Buy
15,507
+10,999
+244% +$392K 0.01% 1710
2013
Q4 		$128K Sell
4,508
-4,097
-48% -$120K ﹤0.01% 1291
2013
Q3 		$308K Buy
8,605
+1,402
+19% +$51.2K 0.01% 1881
2013
Q2 		$241K Buy
+7,203
New +$326K ﹤0.01% 1887

Other funds holding RIGL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

ProShare Advisors's RIGL Position: Q2 2024 in Review

ProShare Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q2 2024, closing a stake of 3,075 shares — an estimated $45.5K sold.

ProShare Advisors first reported a position in RIGL in Q2 2013 and held it in 43 quarters. The position peaked at $602K in Q1 2014. 91 funds tracked by Wall St. Rank hold RIGL as of Q2 2024.

  • ProShare Advisors reported no remaining Rigel Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • ProShare Advisors sold 3,075 Rigel Pharmaceuticals shares in Q2 2024, an estimated $45.5K.
  • ProShare Advisors first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 43 quarters.
  • ProShare Advisors's Rigel Pharmaceuticals position peaked at $602K in Q1 2014.
  • 91 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2024.

Based on ProShare Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.